Article
Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirin.
Journal of viral hepatitis - 1 Mar 2016
Foster G R, Ferenci P, Asselah T, Mantry P, Dufour J-F, Bourlière M, Forton D, Maevskaya M, Wright D, Yoshida E M, García-Samaniego J, Oliveira C, Wright M, Warner N, Sha N, Quinson A-M, Stern J O
Abstract excerpt
Faldaprevir, a hepatitis C virus (HCV) NS3/4A protease inhibitor, was evaluated in HCV genotype 1-infected patients who failed peginterferon and ribavirin (PegIFN/RBV) treatment during one of three prior faldaprevir trials. Patients who received placebo plus PegIFN/RBV and had virological failure during a prior trial were enrolled and treated in two cohorts: prior relapsers (n = 43) and prior nonresponders (null...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.